ClinicalTrials.gg
CompletedNCT00406887Updated Dec 4, 2006

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis

A Phase 3 interventional study of Difluprednate Ophthalmic Emulsion in Anterior Uveitis and Panuveitis, sponsored by Sirion Therapeutics, Inc.. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2006-12-04.

Sponsored by Sirion Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this phase 3 confirmatory study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of treatment of uveitis.

Read the detailed description

The objective of this phase 3 study is to assess the efficacy and safety of 0.05% difluprednate ophthalmic emulsion (DFBA) in patients with endogenous anterior uveitis, in comparison with 0.1% betamethasone sodium phosphate ophthalmic solution (BP).

02

Conditions studied

  • Anterior Uveitis
  • Panuveitis
03

In context

Uveitis, Anterior

56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.

This study's enrollment of 140 is above the median of 50 across 45 interventional studies indexed under Uveitis, Anterior.

Browse Uveitis, Anterior studies →

Lead sponsor

Sirion Therapeutics, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with endogenous anterior uveitis or panuveitis
  • Patients with 10 - 49 anterior chamber cells within one field of the anterior chamber as observed by slit lamp microscopy (criterion for rating of signs 2 or 3)
  • Patients aged ‰1425 years (on the day of obtaining ) who were able to accurately express their own symptoms
  • Patients provided written informed consent prior to initiation of the study

Exclusion criteria

Exclusion Criteria:

  • Patients who did not meet all of the above inclusion criteria
  • Patients received systemic administration of any or drug within the past 1 week prior to instillation of the product
  • Patients received topical injection of any corticosteroid in eyes prior to instillation of the investigational product (Solution formulation: within the past 1 week, depot: within the past 2 weeks)
  • Patients received systemic administration of any non-steroidal anti-inflammatory drug or antiphlogistic enzyme within the past 3 days prior to instillation of the investigational product
  • Patients received instillation of any corticosteroid, non-steroidal anti-inflammatory drug or antiphlogistic enzyme within 12 hours prior to instillation of the investigational product
  • Patients with glaucoma or ocular hypertension
  • Patients with corneal abrasion or ulcer
  • Patients with any confirmed or suspected viral, bacterial or fungal keratoconjunctival disease
  • Patients with allergy to similar drugs such as other corticosteroids
  • Patients requiring use of contact lens during the study period
  • Women who are or might be pregnant, or lactating women
  • Patients participating in another clinical study within the past 3 months before initiation of the present study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
140 participants
06

What researchers measure

Primary outcomes

  1. The difference from the baseline in anterior chamber cell score on Day 14

  2. was compared between the two groups.

Secondary outcomes

  1. The differences from the baseline in anterior chamber cell score on Days 3 and 7

  2. were compared between the two groups.

  3. The numbers of patients with an anterior chamber cell score of 0 on Days 7 and

  4. 14 were compared between the two groups.

  5. The differences from the baseline in total sign and symptom scores on Days 3, 7

  6. and 14 were compared between the two groups.

  7. The numbers of patients with an anterior chamber cell score of 1 or less on Days

  8. 3, 7 and 14 were compared between the two groups.

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00406887
Lead sponsor
Sirion Therapeutics, Inc.
First posted
Dec 4, 2006
Start date
Aug 2002
Completion
Nov 2003
Last update
Dec 4, 2006

Study contacts

Shigeaki Ohno, PhD
principal investigator · Department of Ophthalmology and Visual Science, Graduate School of Medicine, Hokkaido University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difluprednate

Start the discussion